BriaCell Reports Strong Clinical Data and Notable Case in Breast Cancer Treatment

BriaCell Therapeutics Corp., a company specializing in immunotherapy for cancer treatment, has recently announced promising preliminary results from their pivotal Phase 3 study focused on advanced breast cancer patients. The study highlights a noteworthy disease control rate of 61% in Phase 2 patients who were treated with the Bria-IMT™ regimen, a figure that underscores the potential efficacy of their treatment.

In addition, BriaCell reported a 50% disease control rate among patients who had previously undergone antibody-drug conjugate (ADC) therapy and did not experience success. This comparison is significant, especially given the difficult nature of treating individuals who have already failed one or more therapeutic lines.

Dr. Giuseppe Del Priore, the Chief Medical Officer at BriaCell, noted the absence of severe complications that are typically associated with ADC treatments, such as interstitial lung disease (ILD). This observation adds to the evidence supporting Bria-IMT™ as a potential alternative treatment option that could be safer than traditional chemotherapies.

Furthermore, Dr. William V. Williams, BriaCell's President and CEO, remarked on the importance of achieving both survival and quality of life improvements for patients with a very poor prognosis. He emphasized that the company is closely monitoring the ongoing pivotal Phase 3 study and looks forward to providing additional updates as more data become available.

One remarkable case involved a patient who was hormone receptor-positive and HER2-negative, having failed four previous lines of therapy, including ADC treatments. After seven cycles of Bria-IMT™, her liver metastasis was no longer detectable, and her progression-free survival doubled compared to her previous treatment outcomes.

The Phase 2 study involved 35 evaluable patients, 23 of whom were treated with the current version of Bria-IMT™ used in the Phase 3 trial. These patients had an average of six prior regimens. The disease control rate in these patients was 61%, and among those who had failed ADC therapy, the rate was 50%. Additionally, the ADC failure patients exhibited an impressive progression-free survival of 4.2 months, surpassing existing benchmarks in similar populations.

Notably, there were no discontinuations due to drug toxicity and no reported cases of ILD, which is a common and serious side effect associated with ADC therapies. This favorable safety profile contributes to the growing body of evidence that Bria-IMT™ could be a valuable treatment for advanced metastatic breast cancer, especially for patients who have exhausted other therapeutic options.

BriaCell, as a clinical-stage biotechnology firm, continues to advance its research and development efforts to transform cancer treatment with novel immunotherapies. While these results are preliminary, they offer hope for more effective and safer treatment approaches for patients battling advanced stages of breast cancer.